Standard BioTools Inc. Debt Instrument, Convertible, Conversion Ratio
Standard BioTools Inc. (LAB) had Debt Instrument, Convertible, Conversion Ratio of 35.21% as of 2022-03-25, per its 10-K filed 2023-03-14.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentConvertibleConversionRatio1 · last filed 2023-03-14
- 2019-11-30: Debt Instrument, Convertible, Conversion Ratio 1 month 3.45 Rate.
- 2018-03-31: Debt Instrument, Convertible, Conversion Ratio 1 month 0.01 Rate.
Rate
| Period end | Debt Instrument, Convertible, Conversion Ratio 1 month |
|---|---|
| 2019-11-30 | 3.45 Rate 10-Q · filed 2020-08-07 |
| 2018-03-31 | 0.01 Rate 10-Q · filed 2020-08-07 |
pure
| Period end | Debt Instrument, Convertible, Conversion Ratio |
|---|---|
| 2022-03-25 | 35.21% 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |